Shaanxi Panlong Pharmaceutical (SZ:002864) Jing Ji Guan Cha Wang·2025-09-21 05:40Core Insights - The company, Panlong Pharmaceutical, plans to purchase 147 furnished apartments for employee accommodation, with a total transaction price exceeding its net profit for the first half of the year [1][2]. Financial Performance - For the first half of 2025, Panlong Pharmaceutical reported a revenue of 574 million yuan, a year-on-year increase of 26.06%, and a net profit of 60.14 million yuan, a year-on-year increase of 0.81% [1][4]. - The company also achieved a net profit excluding non-recurring items of 52.86 million yuan, reflecting a year-on-year growth of 4.19% [4]. Employee Welfare Initiatives - The acquisition of the "Bicuiyuan" project is aimed at improving the living conditions of employees and ensuring a stable workforce, which is deemed necessary and reasonable for the company's operations [3]. - The company emphasizes its commitment to employee welfare, stating that it aims to create a "spiritual home" for employees and ensure they lead good lives [1][5]. Company Background - Panlong Pharmaceutical was established in 1997 and listed on the Shenzhen Stock Exchange in November 2017, focusing on standardized planting of medicinal materials, drug production, research and development, sales, and pharmaceutical logistics [4]. - As of the end of 2024, the company had a total of 933 employees [4].